Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

BACKGROUND: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468). METHODS: Patients (≥ 18 years of age; N = 414) with active PsA were randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Mease, Philip J., McInnes, Iain B., Rahman, Proton, Ritchlin, Christopher T., Blanco, Ricardo, Dokoupilova, Eva, Andersson, Mats, Kajekar, Radhika, Mpofu, Shephard, Pricop, Luminita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856314/
https://www.ncbi.nlm.nih.gov/pubmed/29544534
http://dx.doi.org/10.1186/s13075-018-1551-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856314/
https://www.ncbi.nlm.nih.gov/pubmed/29544534
http://dx.doi.org/10.1186/s13075-018-1551-x

Ejemplares similares